My Oncologist Never Mentioned Lu-177 PSMA - How to Find Out If You Are Eligible and Get a Second Opinion

Medically reviewed by a nuclear-medicine physician and oncology specialist. Last reviewed: June 2026.

If your prostate cancer has kept growing despite hormone therapy, you may have metastatic castration-resistant prostate cancer, or mCRPC. Lu-177 PSMA therapy is approved to treat this form of advanced prostate cancer. Your oncologist may not have mentioned it. This article explains what to do next.

This guide is for men with mCRPC, a form of prostate cancer that has spread to other parts of the body and no longer responds to hormone-lowering treatment. You'll learn what Lu-177 PSMA therapy is, who may qualify, and how to get a second opinion from a specialist in this treatment.

How to Find Out If You Qualify for Lu-177 PSMA Therapy

1. Confirm your diagnosis is mCRPC - prostate cancer that is metastatic and still growing despite a castrate level of testosterone in your blood.
2. Ask your doctor whether you have had a PSMA-PET scan. This is the imaging test that shows whether your cancer expresses the PSMA protein at a level that makes you a potential candidate.
3. Review your treatment history. Note which hormone therapies (also called androgen receptor pathway inhibitors, or ARPIs) and which chemotherapy drugs you have received, and in what order.
4. Ask for a referral to a nuclear-medicine physician or theranostics specialist. These are the doctors who evaluate and deliver radioligand therapy.
5. Request a second opinion, in person or by teleconsultation, from a center that has a licensed radioligand therapy program.

What Is Lu-177 PSMA Therapy?

Lu-177 PSMA therapy is a type of radioligand therapy. It falls under a field called theranostics, which combines diagnostic imaging with targeted treatment. PSMA stands for prostate-specific membrane antigen, a protein that appears at high levels on most prostate cancer cells.

In this treatment, doctors attach a radioactive molecule to a carrier that seeks out PSMA on cancer cells. When it finds those cells, it delivers radiation directly to them. This targets cancer while sparing nearby healthy tissue.

The medicine is called lutetium Lu 177 vipivotide tetraxetan. Its brand name is Pluvicto. The FDA approved Pluvicto in March 2022 for men with PSMA-positive mCRPC who had already received both an ARPI and taxane-based chemotherapy. In March 2025, the FDA expanded that approval to also include men with mCRPC who have received ARPI therapy and for whom chemotherapy can appropriately be delayed.

Why Your Oncologist May Not Have Brought It Up

There are several common reasons this treatment might not come up in routine appointments:

• This is a relatively new therapy. The FDA approved it in 2022. Oncologists outside large academic or nuclear-medicine centers may not know much about it.
• Delivering this therapy requires a nuclear-medicine physician. Most medical oncologists and urologists don't give radioligand therapy themselves, so they may not refer patients to a specialist.
• Most hospitals don't have the equipment for this therapy. It requires special radiation-safety facilities, licenses, and trained staff.
• In many countries, Lu-177 PSMA therapy is not yet widely available through public health systems. Men in the GCC, sub-Saharan Africa, South Asia, or Southeast Asia may not find this treatment at their local hospital.

None of these reasons disqualify you. The right specialist may just not have reviewed your case yet.

Who May Qualify for Lu-177 PSMA Therapy?

Eligibility is assessed across several factors. Here are the main ones:

• Metastatic castration-resistant prostate cancer (mCRPC). Your cancer must have spread beyond the prostate and must still be growing despite testosterone at a castrate level (below 50 ng/dL or 1.7 nmol/L).
• PSMA-positive disease confirmed by imaging. A PSMA-PET scan must show that your cancer expresses the PSMA protein at a sufficient level. Not all mCRPC is PSMA-positive, which is why the scan is required before any treatment decision.
• Prior ARPI therapy. You must have received at least one androgen receptor pathway inhibitor, such as enzalutamide or abiraterone acetate.
• Chemotherapy history - with updated rules. The original 2022 approval required prior taxane-based chemotherapy such as docetaxel. The 2025 expanded approval lets some men qualify without it, depending on their clinical situation. Ask a specialist which criteria currently apply to you.
• Adequate organ function. Doctors review your kidney, liver, and bone marrow function before treatment to confirm they are acceptable.

If you're not sure whether you meet these criteria, a nuclear-medicine or theranostics specialist can answer that better than your current oncologist, especially if they don't work with radioligand therapy.

What Is a PSMA-PET Scan and Why Does It Matter for Eligibility?

A PSMA-PET scan is a nuclear-medicine imaging test. Doctors inject a small amount of a radiotracer, most often gallium Ga-68 PSMA-11, into your bloodstream. It binds to PSMA-expressing cancer cells, which then appear as bright spots on the scan. This shows where your cancer that expresses PSMA is located in your body.

For Lu-177 PSMA eligibility, the scan must show that cancer expresses PSMA at a high enough level. The VISION clinical trial used a threshold requiring at least one lesion to show uptake greater than liver tissue on the scan. Not every lesion needs to be PSMA-positive, but the overall pattern of disease matters. Eligibility may vary depending on which radiotracer the PET scan uses, so an experienced nuclear-medicine team should review your images.

If you have not yet had a PSMA-PET scan, this is often the most important step toward finding out whether Lu-177 PSMA therapy is an option. Before you request an eligibility review of your PSMA-PET from a verified specialist, make sure you have the scan report and digital images ready to share. The guide on what blood tests and scans you need before Lu-177 PSMA treatment explains what to gather before a specialist review.

What the Evidence From the VISION Trial Shows

The VISION trial, a large randomized phase III study, provides the main evidence for Lu-177 PSMA therapy in mCRPC. It enrolled men with PSMA-positive mCRPC who had received prior ARPI therapy and taxane-based chemotherapy.

The published trial analysis showed that lutetium Lu 177 vipivotide tetraxetan combined with standard care extended overall survival and delayed radiographic disease progression compared with standard care alone. Men in the treatment group survived about 15.3 months on average, compared with 11.3 months in the control group. These figures apply to the specific trial population. They do not predict outcomes for any individual.

The Prostate Cancer Foundation provides a patient-focused summary of what the VISION trial found and what it may mean for men with advanced prostate cancer. Regulators and specialists use these results to decide who qualifies and what treatment to recommend. This is why you should ask your team about this therapy if they haven't mentioned it.

How to Ask for a Second Opinion on Your Lu-177 PSMA Eligibility

Getting a second opinion makes sense when managing complex cancer. Here is a practical way to approach it:

Gather your records first. Collect your pathology reports, a list of all prior treatments with approximate dates, recent PSA results, and all imaging reports. If you have had a PSMA-PET scan, get the written report and the digital images on a disc or via secure transfer.

Ask your oncologist for a referral. Request a referral to a nuclear-medicine physician or a center with an active radioligand therapy program. If your current hospital does not have one, ask which regional or national centers do.

Consider a remote review. Many specialist nuclear-medicine teams now accept digital scan images and medical records for remote eligibility assessments. A teleconsultation lets you get a specialist opinion without traveling first. This matters especially for patients whose countries don't yet offer Lu-177 PSMA therapy.

Ask the right question. When you speak to the specialist, ask directly: based on my disease history and scans, do I meet the criteria for Lu-177 PSMA therapy? If the answer is no, ask what would need to change for you to qualify, and whether that is possible in your situation. Getting a second opinion is a standard step in managing complex cancer. It shows good judgment, not distrust toward your primary team.

Does Chemotherapy Sequencing Affect Your Eligibility?

Yes, and the situation has become more flexible since 2025. The original FDA approval required prior taxane-based chemotherapy such as docetaxel. The 2025 expanded approval lets some men with mCRPC qualify without chemotherapy first, depending on their situation and what their specialist thinks is best.

If your oncologist told you that you must complete chemotherapy before considering Lu-177 PSMA therapy, they may have used the earlier criteria. Ask a specialist to review whether you now qualify under the updated labeling. The article on Lu-177 PSMA after docetaxel - eligibility and sequencing in mCRPC covers in detail how your treatment history shapes access to this therapy.

What If a Specialist Says You Are Not Currently Eligible?

If a specialist says you don't qualify now, that doesn't mean you've run out of treatment options. It means this specific treatment doesn't fit your current situation based on today's evidence.

You may have other approved treatments available, could join a clinical trial, or things might change - like repeating a PSMA-PET scan later after more treatment. A good specialist will explain your alternatives and when it might make sense to revisit the Lu-177 PSMA question. The article on what to do if you don't qualify covers the criteria and alternative paths forward.

For Patients Outside Countries Where Lu-177 PSMA Is Available

For patients in many parts of the GCC, sub-Saharan Africa, South Asia, or Southeast Asia, Lu-177 PSMA therapy exists in other countries but not at home. Regulatory approval status, hospital licensing requirements, and drug supply chains differ significantly between countries.

India is now an established center for international patients seeking this treatment. Several major academic cancer hospitals in India operate licensed radioligand therapy programs with experience treating patients who travel from other countries. The cost per cycle and per full treatment course in India runs substantially lower than in the US, UK, or most of Western Europe. The article on Lu-177 PSMA therapy cost in India vs the US shows what international patients typically pay.

Before booking travel, confirm your eligibility with a specialist. This is the most important protective step. Have a specialist review your PSMA-PET images and medical history before you travel. This prevents costly travel to a center that can't treat you.

When to Talk to Your Doctor

Raise this topic with your oncologist or ask for a specialist referral if:

• Your prostate cancer has become castration-resistant and they haven't mentioned Lu-177 PSMA therapy
• You've never had a PSMA-PET scan and want to know if you should
• You've received ARPI therapy and want to learn your current options
• Your team said you're not a candidate and you want to know why and what alternatives exist

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.